Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 39-46

  Ansari, Jawaher ^a   Hussain, Syed A ^b   Ansari, Asif ^c   Glaholm, John ^d  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clear cell carcinoma; Metastatic RCC; Molecular targeted agent; Vascular endothelial growth factor receptor inhibitor

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENOTYPE ENVIRONMENT INTERACTION; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

EID: 84874838008     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S25862     Document Type: Review

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993;20(2):283-295.
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688-696.
4. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998;22(3):200-209.
5. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282(28):20534-20543.
6. Motzer RJ, Hutson TE, Tomczak P, etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
7. Sternberg CN, Davis ID, Mardiak J, etal. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
8. Hudes G, Carducci M, Tomczak P, etal; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
9. Escudier B, Pluzanska A, Koralewski P, etal; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
10. Escudier B, Bellmunt J, Négrier S, etal. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28(13):2144-2150.
11. Rini BI, Halabi S, Rosenberg JE, etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33): 5422-5428.
12. Rini BI, Halabi S, Rosenberg JE, etal. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
13. Escudier B, Eisen T, Stadler WM, etal. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
14. Motzer RJ, Escudier B, Oudard S, etal; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637): 449-456.
15. Motzer RJ, Escudier B, Oudard S, etal; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
16. Calvo E, Escudier B, Motzer RJ, etal. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333-339.
17. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008;9(6): 658-671.
18. Kelly RJ, Rixe O. Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009;4(4): 297-305.
19. Hu-Lowe DD, Zou HY, Grazzini ML, etal. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272-7283.
20. Rugo HS, Herbst RS, Liu G, etal. Phase I trial of the oral antiangiogenesis agent AG-013736in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474-5483.
21. Rini B et al. Phase 2 study of Axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4462-4468.
22. Dutcher JP, Wilding GR, Hudes WM, etal. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol. 2008;26(Suppl):Abstr 5127.
23. Rixe O, Bukowski RM, Michaelson MD, etal. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975-984.
24. Motzer RJ, de La Motte Rouge T, Harzstark AL, etal. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol. 2011;29(Suppl):Abstr 4547.
25. Rini BI, Escudier B, Tomczak P, etal. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
26. Pfizer. Axitinib (AG-013736) with or without dose titration (increase) in patients with kidney cancer. In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 9, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00835978. NLM identifier: NCT00835978. Accessed November 23, 2012.
27. Cella D, Escudier B, Rini BI, etal. Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2011;29(Suppl):Abstr 4504.
28. Pfizer. Axitinib (AG-013736) for the treatment of metastatic renal cell cancer. In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 19, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00920816. NLM identifier: NCT00920816. Accessed November 23, 2012.
29. Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs Sorafenib as Second Line Therapy in Metastatic Renal Cell Carcinoma: Results From the INTORSECT Trial. Presented at the 37th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, 2012. Abstract LBA22.